[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"other-map-k-pathway-driven-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:other-map-k-pathway-driven-diseases":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":4,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":16,"phases":4,"briefSummary":17,"conditions":18,"keywords":22,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":33,"locationsCount":4},"100441423",false,"NCT05028166","Individual Patient Compassionate Use of Mirdametinib","Inclusion Criteria:\n\n* Patient has a serious, debilitating or life-threatening medical condition that cannot be treated satisfactorily with an authorized medicinal product or other available standard treatment options, or all other treatment options have been exhausted.\n* Patient does not qualify to participate in an ongoing clinical trial.","ALL","2 Years","EXPANDED_ACCESS","This program is being offered on a patient by patient basis and will require company, Institutional Review Board\u002FIndependent Ethics Committee, and applicable competent authority approval.",[19,20,21],"Neurofibromatosis Type 1-Associated Plexiform Neurofibromas","Histiocytic Neoplasm","Other MAP-K Pathway Driven Diseases",[23,24,25,26,27],"RASopathies","NF1","Neurofibromatosis","Plexiform Neurofibromas","Langerhans","AVAILABLE","2026-05-04",{"date":31,"type":32},"2026-05-08","ACTUAL",{"name":34,"class":35},"SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany","INDUSTRY",""]